Keywords: Asterand, Capsant Neurotech, Diabetes assay platform

Asterand licenses diabetes assay platform from Capsant Neurotech

Article | 09 June 2011

Asterand (LSE: ATD), a provider of human tissue and cell-based services to pharmaceutical and biotechnology companies, has acquired an exclusive ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Asterand

Capsant Neurotechnologies

Go to company listing